145 related articles for article (PubMed ID: 17296563)
41. Epigenetic control of MAGE gene expression by the KIT tyrosine kinase.
Yang B; Wu J; Maddodi N; Ma Y; Setaluri V; Longley BJ
J Invest Dermatol; 2007 Sep; 127(9):2123-8. PubMed ID: 17495964
[TBL] [Abstract][Full Text] [Related]
42. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
43. DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia.
Lin J; Chen Q; Yang J; Qian J; Deng ZQ; Qian W; Chen XX; Ma JC; Xiong DS; Ma YJ; An C; Tang CY
Leuk Res; 2014 May; 38(5):601-7. PubMed ID: 24656837
[TBL] [Abstract][Full Text] [Related]
44. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
45. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
[TBL] [Abstract][Full Text] [Related]
46. Imatinib restores expression of CD62L in BCR-ABL-positive cells.
Fruehauf S; Topaly J; Schad M; Paschka P; Gschaidmeier H; Zeller WJ; Hochhaus A; Ho AD
J Leukoc Biol; 2003 May; 73(5):600-3. PubMed ID: 12714574
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
Bixby D; Talpaz M
Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
[TBL] [Abstract][Full Text] [Related]
48. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
49. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
[TBL] [Abstract][Full Text] [Related]
50. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
51. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
52. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
53. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
54. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
55. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
56. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers.
Mathieu MG; Linley AJ; Reeder SP; Badoual C; Tartour E; Rees RC; McArdle SE
Cancer Immun; 2010 Jan; 10():2. PubMed ID: 20058853
[TBL] [Abstract][Full Text] [Related]
57. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Riley CL; Mathieu MG; Clark RE; McArdle SE; Rees RC
Cancer Immunol Immunother; 2009 Sep; 58(9):1489-99. PubMed ID: 19259670
[TBL] [Abstract][Full Text] [Related]
58. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.
Heller G; Topakian T; Altenberger C; Cerny-Reiterer S; Herndlhofer S; Ziegler B; Datlinger P; Byrgazov K; Bock C; Mannhalter C; Hörmann G; Sperr WR; Lion T; Zielinski CC; Valent P; Zöchbauer-Müller S
Leukemia; 2016 Sep; 30(9):1861-8. PubMed ID: 27211271
[TBL] [Abstract][Full Text] [Related]
59. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia.
Yang H; Liang H; Yan JS; Tao R; Hao SG; Ma LY
Int J Hematol; 2012 Jul; 96(1):65-73. PubMed ID: 22674382
[TBL] [Abstract][Full Text] [Related]
60. Expression of testis-specific genes, TEX101 and ODF4, in chronic myeloid leukemia and evaluation of TEX101 immunogenicity.
Ghafouri-Fard S; Modarressi MH; Yazarloo F
Ann Saudi Med; 2012; 32(3):256-61. PubMed ID: 22588436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
